

Yusuke Moritoh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/120934/publications.pdf>

Version: 2024-02-01

13
papers

255
citations

932766

10
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

303
citing authors

#	ARTICLE	IF	CITATIONS
1	Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice. <i>Pharmacological Research</i> , 2021, 163, 105337.	3.1	16
2	Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 86-96.	2.2	8
3	Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. <i>Molecular Pharmacology</i> , 2021, 99, 286-293.	1.0	2
4	SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. <i>Diabetes</i> , 2021, 70, 2364-2376.	0.3	14
5	The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals. <i>Nature Communications</i> , 2021, 12, 4847.	5.8	41
6	Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 631-640.	0.4	5
7	The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 21-27.	1.3	18
8	Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10352-10379.	2.9	21
9	Discovery and characterization of a small molecule enteropeptidase inhibitor, SCO-792. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00517.	1.1	13
10	GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. <i>PLoS ONE</i> , 2019, 14, e0222653.	1.1	11
11	SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 172-181.	1.3	32
12	SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2228-2239.	2.2	16
13	Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice. <i>Scientific Reports</i> , 2016, 6, 32072.	1.6	58